X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-07-24 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $117.80 | -15,000 | 6,871,164 | 0% | -$1,766,972 | ||||||
2024-07-25 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $5.42 | -11,886 | 73,136 | -14% | -$64,370 | ||||||
| DM | 2024-07-24 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Dir | S - Sale+OE | $13.88 | -27,590 | 408,035 | -6% | -$382,934 | |||||
2024-07-24 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $27.76 | -2,813 | 144,926 | -2% | -$78,089 | ||||||
2024-07-24 | IMVT | Immunovant, Inc. | Geffner Michael | Chief Medical Officer | S - Sale | $27.76 | -3,456 | 138,160 | -2% | -$95,939 | ||||||
2024-07-24 | IMVT | Immunovant, Inc. | Levine Mark S. | GC | S - Sale | $27.76 | -4,015 | 333,394 | -1% | -$111,456 | ||||||
2024-07-23 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $8.48 | -11,447 | 7,155,663 | 0% | -$97,041 | ||||||
| M | 2024-07-23 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $2.52 | -1,800 | 368,292 | 0% | -$4,529 | |||||
2024-07-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $56.63 | -2,207 | 171,212 | -1% | -$124,971 | ||||||
| DM | 2024-07-23 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | S - Sale+OE | $55.00 | -20,000 | 168,176 | -11% | -$1,100,023 | |||||
| D | 2024-07-23 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale+OE | $84.26 | -15,000 | 765,764 | -2% | -$1,263,912 | |||||
| M | 2024-07-22 | ATYR | Atyr Pharma Inc | Schimmel Paul | Dir | P - Purchase | $1.85 | +100,000 | 1,101,056 | +10% | +$184,613 | |||||
| D | 2024-07-22 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $12.00 | +8,333,333 | 826,832 | -111% | +$99,999,996 | |||||
| D | 2024-07-22 | ARTV | Artiva Biotherapeutics, Inc. | 5Am Partners Vi, LLC | 10% | P - Purchase | $12.00 | +833,333 | 2,353,304 | +55% | +$9,999,996 | |||||
2024-07-19 | BCLI | Brainstorm Cell Therapeutics Inc. | Dagher Ibrahim B. | Chief Medical Officer | S - Sale | $0.35 | -63,000 | 190,000 | -25% | -$22,069 | ||||||
| D | 2024-07-22 | HALO | Halozyme Therapeutics, Inc. | Labrosse Nicole | SVP, CFO | S - Sale+OE | $53.93 | -5,000 | 15,480 | -24% | -$269,662 | |||||
| M | 2024-07-19 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.74 | -960 | 74,217 | -1% | -$715 | |||||
2024-07-19 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.75 | -9,731 | 773,251 | -1% | -$7,299 | ||||||
| M | 2024-07-19 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.74 | -3,400 | 17,836,760 | 0% | -$2,530 | |||||
| M | 2024-07-19 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.74 | -1,391 | 507,525 | 0% | -$1,035 | |||||
| D | 2024-07-22 | ARTV | Artiva Biotherapeutics, Inc. | Venbio Global Strategic Fund Iii, L.P. | 10% | P - Purchase | $12.00 | +416,666 | 1,936,637 | +27% | +$4,999,992 | |||||
| D | 2024-07-22 | ARTV | Artiva Biotherapeutics, Inc. | Gc Corp. | 10% | P - Purchase | $12.00 | +2,083,332 | 4,567,412 | +84% | +$24,999,984 | |||||
| D | 2024-07-22 | ARTV | Artiva Biotherapeutics, Inc. | Huh Yong-Jun | Dir | P - Purchase | $12.00 | +2,083,332 | 4,567,412 | +84% | +$24,999,984 | |||||
2024-07-19 | EDIT | Editas Medicine, Inc. | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | S - Sale | $5.21 | -6,619 | 134,413 | -5% | -$34,456 | ||||||
| D | 2024-07-18 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $81.17 | -8,000 | 96,720 | -8% | -$649,325 | |||||
2024-07-17 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $122.84 | -15,000 | 6,886,164 | 0% | -$1,842,651 | ||||||
2024-07-17 | IMVT | Immunovant, Inc. | Levine Mark S. | GC | S - Sale | $29.69 | -2,505 | 337,409 | -1% | -$74,382 | ||||||
2024-07-17 | IMVT | Immunovant, Inc. | Macias William L. | Chief Medical Officer | S - Sale | $29.69 | -3,044 | 371,359 | -1% | -$90,386 | ||||||
2024-07-17 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $29.69 | -3,123 | 347,544 | -1% | -$92,733 | ||||||
2024-07-17 | IMVT | Immunovant, Inc. | Butchko Julia G. | Chief Development Officer | S - Sale | $29.69 | -2,867 | 443,986 | -1% | -$85,132 | ||||||
2024-07-17 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $29.69 | -8,685 | 1,023,412 | -1% | -$257,888 | ||||||
| DM | 2024-07-17 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $51.48 | -35,000 | 220,937 | -14% | -$1,801,625 | |||||
2024-07-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $6.47 | -14,851 | 146,049 | -9% | -$96,125 | ||||||
2024-07-17 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO | S - Sale | $6.47 | -22,528 | 330,735 | -6% | -$145,815 | ||||||
2024-07-17 | CADL | Candel Therapeutics, Inc. | Schoch Charles | See Remarks | S - Sale | $6.47 | -9,884 | 62,520 | -14% | -$63,975 | ||||||
2024-07-17 | CADL | Candel Therapeutics, Inc. | Nichols William Garrett | Chief Medical Officer | S - Sale | $6.47 | -10,875 | 114,482 | -9% | -$70,390 | ||||||
2024-07-17 | CADL | Candel Therapeutics, Inc. | Barone Francesca | Chief Scientific Officer | S - Sale | $6.47 | -14,051 | 159,961 | -8% | -$90,947 | ||||||
| M | 2024-07-17 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | P - Purchase | $8.26 | +216,264 | 2,287,064 | +10% | +$1,785,662 | |||||
| D | 2024-07-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $27.11 | -1,750 | 6,781 | -21% | -$47,443 | |||||
| D | 2024-07-16 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $65.30 | -10,901 | 9,278 | -54% | -$711,854 | |||||
| D | 2024-07-16 | NBIX | Neurocrine Biosciences Inc | Cooke Julie | CHRO | S - Sale+OE | $150.04 | -900 | 18,202 | -5% | -$135,036 | |||||
| DM | 2024-07-16 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Dir | S - Sale+OE | $13.77 | -2,410 | 408,035 | -1% | -$33,192 | |||||
| D | 2024-07-16 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $150.03 | -2,857 | 6,607 | -30% | -$428,627 | |||||
| D | 2024-07-16 | NBIX | Neurocrine Biosciences Inc | Lyons Gary A | Dir | S - Sale+OE | $150.03 | -930 | 119,047 | -1% | -$139,530 | |||||
| D | 2024-07-16 | NBIX | Neurocrine Biosciences Inc | Abernethy Matt | CFO | S - Sale+OE | $150.04 | -900 | 31,528 | -3% | -$135,037 | |||||
| D | 2024-07-16 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $150.00 | -7,004 | 39,740 | -15% | -$1,050,590 | |||||
| D | 2024-07-16 | VCEL | Vericel Corp | Flynn Sean C. | GC | S - Sale+OE | $52.18 | -15,000 | 707 | -95% | -$782,700 | |||||
2024-07-16 | TARA | Protara Therapeutics, Inc. | Opaleye Management Inc. | 10% | S - Sale | $2.44 | -11,396 | 2,210,027 | -1% | -$27,828 | ||||||
| D | 2024-07-15 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $46.47 | -16,667 | 269,073 | -6% | -$774,516 | |||||
| D | 2024-07-16 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance | S - Sale+OE | $85.00 | -5,000 | 12,723 | -28% | -$425,000 | |||||
| DM | 2024-07-15 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Chief Medical Officer | S - Sale+OE | $45.53 | -39,600 | 95,470 | -29% | -$1,803,143 | |||||
| D | 2024-07-12 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $45.04 | -35,000 | 802,913 | -4% | -$1,576,322 | |||||
2024-07-15 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale | $121.12 | -15,000 | 1,598,138 | -1% | -$1,816,800 | ||||||
2024-07-12 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | CFO | S - Sale | $50.00 | -5,000 | 14,436 | -26% | -$250,000 | ||||||
| D | 2024-07-11 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $25.00 | -1,996 | 6,781 | -23% | -$49,900 | |||||
2024-07-11 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $5.97 | -13,330 | 160,900 | -8% | -$79,625 | ||||||
2024-07-11 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO | S - Sale | $5.97 | -20,293 | 353,263 | -5% | -$121,218 | ||||||
2024-07-11 | CADL | Candel Therapeutics, Inc. | Schoch Charles | See Remarks | S - Sale | $5.97 | -8,897 | 72,404 | -11% | -$53,145 | ||||||
2024-07-11 | CADL | Candel Therapeutics, Inc. | Nichols William Garrett | Chief Medical Officer | S - Sale | $5.97 | -9,769 | 125,357 | -7% | -$58,354 | ||||||
2024-07-11 | CADL | Candel Therapeutics, Inc. | Barone Francesca | Chief Scientific Officer | S - Sale | $5.97 | -12,645 | 174,012 | -7% | -$75,534 | ||||||
2024-07-10 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $117.08 | -15,000 | 6,901,164 | 0% | -$1,756,177 | ||||||
| DM | 2024-07-10 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $7.48 | -100,000 | 758,738 | -12% | -$747,500 | |||||
| DM | 2024-07-11 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $60.08 | -5,451 | 9,278 | -37% | -$327,477 | |||||
| D | 2024-07-10 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | CEO | S - Sale+OE | $22.49 | -12,923 | 1,059,153 | -1% | -$290,598 | |||||
| DM | 2024-07-10 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale+OE | $16.79 | -55,000 | 120,695 | -31% | -$923,388 | |||||
| M | 2024-07-09 | TARA | Protara Therapeutics, Inc. | Opaleye Management Inc. | 10% | S - Sale | $2.36 | -74,551 | 2,221,423 | -3% | -$175,842 | |||||
| DM | 2024-07-09 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $7.28 | -30,000 | 1,316,593 | -2% | -$218,354 | |||||
2024-07-09 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $7.32 | -11,447 | 7,167,110 | 0% | -$83,735 | ||||||
2024-07-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $48.91 | -842 | 73,602 | -1% | -$41,185 | ||||||
| D | 2024-07-09 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $56.63 | -1,500 | 0 | -100% | -$84,947 | |||||
2024-07-09 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $28.06 | -4,747 | 350,667 | -1% | -$133,201 | ||||||
2024-07-09 | IMVT | Immunovant, Inc. | Butchko Julia G. | Chief Development Officer | S - Sale | $28.06 | -1,527 | 446,853 | 0% | -$42,848 | ||||||
2024-07-09 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $28.06 | -4,619 | 1,032,097 | 0% | -$129,609 | ||||||
2024-07-09 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $40.83 | -2,399 | 47,088 | -5% | -$97,951 | ||||||
| D | 2024-07-09 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | S - Sale+OE | $44.00 | -2,155 | 19,948 | -10% | -$94,820 | |||||
2024-07-05 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $16.33 | -8,000 | 123,942 | -6% | -$130,640 | ||||||
| D | 2024-07-08 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance | S - Sale+OE | $80.00 | -5,000 | 12,723 | -28% | -$400,000 | |||||
2024-07-09 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $38.21 | -453,960 | 723,246 | -39% | -$17,346,919 | ||||||
| D | 2024-07-08 | MRNA | Moderna, Inc. | Mock James M | CFO | S - Sale+OE | $118.24 | -689 | 7,269 | -9% | -$81,465 | |||||
2024-07-05 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Principal Accounting Officer | S - Sale | $3.83 | -1,610 | 13,944 | -10% | -$6,166 | ||||||
2024-07-05 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale | $45.00 | -545 | 1,033 | -35% | -$24,525 | ||||||
| D | 2024-07-05 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $6.03 | -1,173 | 46,457 | -2% | -$7,073 | |||||
2024-07-05 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $37.26 | -15,000 | 1,474,487 | -1% | -$558,900 | ||||||
2024-07-03 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $37.60 | -5,995 | 294,793 | -2% | -$225,418 | ||||||
2024-07-02 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $48.00 | -126 | 79,705 | 0% | -$6,048 | ||||||
| D | 2024-07-02 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $48.00 | -1,114 | 504,732 | 0% | -$53,474 | |||||
2024-07-02 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $48.00 | -322 | 89,974 | 0% | -$15,457 | ||||||
2024-07-02 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $48.00 | -476 | 173,419 | 0% | -$22,849 | ||||||
| D | 2024-07-02 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $0.33 | -13,520 | 195,058 | -6% | -$4,408 | |||||
| D | 2024-07-02 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $0.33 | -49,162 | 1,043,626 | -4% | -$16,027 | |||||
| M | 2024-06-13 | DNLI | Denali Therapeutics Inc. | Krognes Steve E. | Dir | S - Sale | $22.11 | -30,688 | 872,620 | -3% | -$678,660 | |||||
2024-07-01 | DNLI | Denali Therapeutics Inc. | Sato Vicki L | Dir | S - Sale | $22.14 | -3,080 | 119,256 | -3% | -$68,204 | ||||||
| D | 2024-07-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $21.36 | -4,248 | 1,737 | -71% | -$90,758 | |||||
2024-07-02 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.72 | -379 | 508,916 | 0% | -$273 | ||||||
2024-07-02 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.72 | -939 | 17,840,160 | 0% | -$676 | ||||||
2024-07-02 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.72 | -304 | 75,177 | 0% | -$219 | ||||||
2024-07-02 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.72 | -1,489 | 782,982 | 0% | -$1,072 | ||||||
| M | 2024-07-01 | BEAM | Beam Therapeutics Inc. | Simon Amy | Chief Medical Officer | S - Sale | $23.28 | -1,250 | 68,805 | -2% | -$29,094 | |||||
| D | 2024-07-01 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $55.39 | -20,000 | 9,278 | -68% | -$1,107,763 | |||||
2024-07-01 | TARA | Protara Therapeutics, Inc. | Opaleye Management Inc. | 10% | S - Sale | $2.12 | -8,288 | 2,300,974 | 0% | -$17,598 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |